Figure 1.
Survival time of patients vaccinated with CIMAvax-EGF. The median overall survival was 14.6 months while survival rates at 6, 12, and 24 months were 82.1%, 57.2%, and 37.6%, respectively.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.